Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogenic gamma delta T cell therapy - Beijing GD Initiative Cell Therapy Technology

Next Previous
Drug Profile

Allogenic gamma delta T cell therapy - Beijing GD Initiative Cell Therapy Technology

Alternative Names: Ex vivo expanded allogeneic γδT cells - Beijing GD Initiative Cell Therapy Technology

Latest Information Update: 02 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing GD Initiative Cell Therapy
  • Developer Beijing GD Initiative Cell Therapy; Chinese Academy of Medical Sciences
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver cancer

Most Recent Events

  • 18 Apr 2024 Allogenic gamma delta T cell therapy is still in phase I trials for Liver cancer (Second-line therapy or greater) in China (Parenteral)
  • 18 Apr 2024 Beijing GD Initiative Cell Therapy Technology plans a phase I trial for Liver cancer (First line therapy, Combination therapy) in April 2024 (NCT06364787)
  • 18 Apr 2024 Beijing GD Initiative Cell Therapy Technology plans a phase 0 trial for Liver cancer (Combination therapy) in April 2024 (NCT06364800)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top